Formulary guidance and transparency from P&T to point of care


Reality Check on Type 2 Diabetes (DPP4 and Combo) 

Market access for type 2 Diabetes (DPP4 and Combo) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 40% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In December 2019, Lexicon Pharmaceuticals, Inc. reported topline data from their Phase III SOTA-EMPA study for Zynquista (sotagliflozin) in type 2 diabetes, according to the company
  • Key Findings: Merck's Januvia and combos have the best coverage. Lilly/BI is second best here overall, with Tradjenta (linagliptin) and combos. AstraZeneca's Onglyza (saxagliptin) and combos are a distant third. Takeda, the last to launch a DPP-4, never got a lot of traction and is a distant fourth

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.